Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Sonata Prescribers (US)

Analysis of: Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study (www.fiercebiotech.com)
This study reveals the nature of the disease- it affects both men and women.   This study confirms the benefit of use of Gardasil in boys and men.   
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof (online.wsj.com)
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
Louis Sanfilippo, MD, President
Louis Sanfilippo, MD, President
LCS Group, LLC
Analysis of: AstraZeneca Announces European SEROQUEL XR Submission for the Treatment of Generalised Anxiety Disorder (www.pharmalive.com)
Astra Zeneca is pursuing important medical and, of course, commercial goals by seeking the expanded clinical indications of major depression and generalized anxiety disorder for Seroquel XR, heir to blockbuster Seroquel (quetiapine).  This latest EU submission culminates regulatory submissions...
September 2, 2008
Byetta Saves Lives
Analysis of: FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta (www.fda.gov)
1.Hypertriglyceridemia causes pancreatitis 2.Most PCP, endocrinologists, and cardiologists are not effectively treating high triglycerides, and may make it worse by recommending a low fat = high carb diet 3.Accord data with 75% reduction in death, and patients desparate for wt loss will continue to...
Analysis of: Heart Stents No Better Than Drugs for Chest Pain Over Time (www.bloomberg.com)
Most hospitals are financially built on their heart programs. The "agressive" medical arm is conservative by our standards yet as good as stents at far less cost. If this was truly pursued by large companies with TPA insurance plans, their overall cost would drop with large savings in healthcare costs....
August 18, 2008
Byetta saves lives
Analysis of: Lilly Diabetes Drug Shows a Life-Extending Promise (www.nytimes.com)
The ACCORD trial results were no suprise to our diabetes practice. We have been heavy users of Byetta since launch in 2005, and have seen the same results in our population of > 2000 diabetics with over 700 on Byetta. Since the Simpson et al study in the Canadian Journal of Medicine (CMAJ 2006;174(2):169-74)...
Analysis of: New Treatment Halts Progress of Alzheimer's Disease (www.abdn.ac.uk)
While the clinical trial data remain unpublished, those who attended the ICAD conference remain concerned about the possibility that the effects are not as pronounced as the interpretation by the investigators.
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy (www.medicalnewstoday.com)
-Pharmacogenetic tests have not made it into the treatment or assessment process for most physicians. -Until the cost for these tests become negligible -- or, included in the cost of a particular antidepressant -- psychopharmacogenetic testing will not make it into the mainstream. 
Louis Sanfilippo, MD, President
Louis Sanfilippo, MD, President
LCS Group, LLC
Analysis of: TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy (www.medicalnewstoday.com)
“Personalized medical diagnositics” looks to be evolving as a high impact area in neuropsychiatric drug development.  Such ‘genetic biomarker’ platforms, based on either pharmacogenetic profiles coming from DNA blueprints or gene products from a simple blood draw, aim to identify patients who are...
Louis Sanfilippo, MD, President
Louis Sanfilippo, MD, President
LCS Group, LLC
Analysis of: One drug, many uses. Good idea? (www.indystar.com)
‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 123

Analytics


Generated at 2009-01-09T13:00:20.343